Categories Health Care, U.S. Markets News

NASH drug developer Genfit plans $132-million US IPO, to list on Nasdaq

France-based biopharmaceutical firm Genfit (EPA: GNFT) has launched a global offering of its American Depository Shares and ordinary shares to raise around $132 million. The company also intends to list as “GNFT” on the Nasdaq Global Market.

An SEC filing by the company indicated last week that the main purpose of the offering is to take forward the development of the treatment for non-alcoholic steatohepatitis, or NASH, a type of fatty liver disease that is becoming common mainly due to the unhealthy food habits among the people. In the offering, the company intends to issue and sell about five million shares at $26.33 per share to investors. It also plans a private placement of its ordinary shares in Europe and other countries, simultaneously.

Genfit is looking to use $15 million of the proceeds from the offering to prepare for the commercialization of elafibranor, the drug candidate for NASH. Around $50 million will be used for the completion of the phase-III study of elafibranor and the further procedures – up to submission of new drug applications in the US and Europe. The company plans to use around $35 million of the remaining proceeds to initiate and complete the phase-III study of elafibranor for the treatment of primary biliary cholangitis.

An SEC filing by the company indicated last week that the main purpose of the offering is to take forward the development of its NASH drug

It is expected that the global offering and the private placement will close simultaneously on the third trading day after the final pricing and allocation of the offering.

Genfit is specialized in the development of drugs and diagnostic solutions for the treatment of various liver diseases. Elafibranor, the company’s lead drug candidate, has reached the final stages of development for the treatment of NASH, giving it an advantage over rivals. Recently, Genfit received FDA approval for the phase-II clinical trial of elafibranor for non-alcoholic steatohepatitis in children and adolescents.

Also read: Zynerba Pharmaceuticals receives US patent for its CBD gel

Meanwhile, the underwriters for the global offering have been granted a 30-day option to buy additional ADS and ordinary shares valued up to 15% of the total number of shares being offered. Excluding the underwriters’ option to purchase additional shares, the offering is expected to result in the dilution of about 14% of Genfit’s outstanding share capital.

After slipping to a two-year low in the final weeks of last year, Genfit shares have gained more than 40% on the Euronext Paris stock exchange. The stock is currently trading slightly below the levels seen a year earlier.

 

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

Most Popular

Key highlights from Deere & Co.’s (DE) Q4 2024 earnings results

Deere & Company (NYSE: DE) reported its fourth quarter 2024 earnings results today. Worldwide net sales and revenues decreased 28% year-over-year to $11.14 billion. Net income was $1.24 billion, or

NVDA Earnings: Nvidia Q3 profit jumps, beats estimates

NVIDIA Corporation (NASDAQ: NVDA) on Wednesday reported a sharp increase in adjusted profit and revenue for the third quarter of 2025. Earnings also topped analysts' estimates. The tech firm’s revenues

Lowe’s Companies (LOW): A few points to note about the Q3 2024 performance

Shares of Lowe’s Companies, Inc. (NYSE: LOW) rose over 1% on Wednesday. The stock has gained 8% over the past three months. The company delivered better-than-expected earnings results for the

Comments

  1. Pingback: Academic Year
  2. Pingback: attendance
  3. Pingback: Webmaster
  4. Pingback: Fiverr Earn
  5. Pingback: Fiverr Earn
  6. Pingback: Fiverr Earn
  7. Pingback: Fiverr Earn
  8. Pingback: fiverrearn.com
  9. Pingback: fiverrearn.com
  10. Pingback: liv pure
  11. Pingback: TMS System
  12. Pingback: quietum plus buy
  13. Pingback: fiverrearn.com
  14. Pingback: weather tomorrow
  15. Pingback: clima para mañana
  16. Pingback: fiverrearn.com
  17. Pingback: french bulldog
  18. Pingback: fiverrearn.com
  19. Pingback: fluffy frenchies
  20. Pingback: aussiedoodle
  21. Pingback: Yo.fan approval
  22. Pingback: crypto news
  23. Pingback: future university
  24. Pingback: Warranty
  25. Pingback: FUE
  26. Pingback: Interstate moving
  27. Pingback: Classic Books 500
  28. Pingback: FiverrEarn
  29. Pingback: Streamer
  30. Pingback: FiverrEarn
  31. Pingback: OnlyFans Australia
  32. Pingback: partners
  33. Pingback: FiverrEarn
  34. Pingback: FiverrEarn
  35. Pingback: FiverrEarn
  36. Pingback: FiverrEarn
  37. Pingback: FiverrEarn
  38. Pingback: FiverrEarn
  39. Pingback: FiverrEarn
  40. Pingback: FiverrEarn
  41. Pingback: FiverrEarn
  42. Pingback: FiverrEarn
  43. Pingback: FiverrEarn
  44. Pingback: FiverrEarn
  45. Pingback: FiverrEarn
  46. Pingback: Butter
  47. Pingback: christmas
  48. Pingback: Slot Thailand
  49. Pingback: Kuliah Termurah
  50. Pingback: FiverrEarn
  51. Pingback: FiverrEarn
  52. Pingback: cheap sex cams
  53. Pingback: dehydrated water
  54. Pingback: frt trigger
  55. Pingback: prestanombres
  56. Pingback: Derecho fiscal
  57. Pingback: Ice Kream Vapes
  58. Pingback: 늑대닷컴
  59. Pingback: Multi-payline slot
  60. Pingback: One Peace AMV
  61. Pingback: nangs near me
  62. Pingback: superslot
  63. Pingback: allgame
  64. Pingback: 918kiss
  65. Pingback: หวย24
  66. Pingback: Best cleanser
  67. Pingback: pg slot
  68. Pingback: cybersécurité
  69. Pingback: aplikasi judi slot
  70. Pingback: megagame
  71. Pingback: contratar sicario
  72. Pingback: itme.xyz
  73. Pingback: itme.xyz
  74. Pingback: itme.xyz
  75. Pingback: itme.xyz
  76. Pingback: ItMe.Xyz
  77. Pingback: Bokeo Thailand
  78. Pingback: Bokeo Thailand
  79. Pingback: ItMe.Xyz
  80. Pingback: MasumINTL.Com
  81. Pingback: ItMe.Xyz
  82. Pingback: ItMe.Xyz
Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top